Expression and Prognosis Role of Indoleamine 2,3-dioxygenase in Hepatocellular Carcinoma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2008 Apr 29

PMID 18438685

Citations 83

Authors

Ke Pan

Hui Wang

Min-Shan Chen

Hua-Kun Zhang

De-Sheng Weng

Jun Zhou

Wei Huang

Jian-Jun Li

Hai-Feng Song

Jian-Chuan Xia

Affiliations

Soon will be listed here.

Abstract

Purpose: Immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) plays an important role in immune tolerance. In some malignancies, the evidences were given to show that overexpression of IDO was related to poor prognosis of cancer patients.

Methods: In this study, we investigated IDO expression in hepatocellular carcinoma (HCC) cell lines and 138 primary HCC clinical surgical specimens, and correlation of IDO expression with clinical outcomes and prognosis of HCC patients.

Results: Reverse transcription-PCR analysis showed that in vitro IDO expression in HCC cell lines and non-cancerous liver cell line were dependent on IFN-gamma. Immunohistochemical detection revealed that IDO was overexpressed in 49 of 138 (35.5%) tumor resection samples, whereas 89 of 138 (64.5%) cases showed weak immunostaining. IDO overexpression was significantly correlated with high metastasis rates (P = 0.049). Kaplan-Meier survival curves showed that overexpression of IDO resulted in significantly poor prognosis (P = 0.017, log-rank test). Multivariate Cox's analysis showed that IDO expression was an independent prognostic factor for overall survival of HCC patients (P = 0.010).

Conclusion: Our data indicated that IDO may be a novel favorable prognostic indicator and candidate adjuvant therapeutic target for HCC.

Citing Articles

Integrated analyses reveal IDO1 as a prognostic biomarker coexpressed with PD-1 on tumor-associated macrophages in esophageal squamous cell carcinoma.

Peng Y, Wang L, Yang J, Wu Q, Sun X, Zhang J Front Pharmacol. 2024; 15:1466779.

PMID: 39351094 PMC: 11439782. DOI: 10.3389/fphar.2024.1466779.

Mechanisms of Tolerance Induction in Liver Transplantation: Lessons Learned from Fetomaternal Tolerance, Autoimmunity and Tumor Immunity.

Nakano T, Goto S, Chen C Int J Mol Sci. 2024; 25(17).

PMID: 39273280 PMC: 11395488. DOI: 10.3390/ijms25179331.

Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis.

Zhuo X, Deng H, Qiu M, Qiu X Breast Cancer Res Treat. 2024; 207(1):151-165.

PMID: 38780888 PMC: 11230954. DOI: 10.1007/s10549-024-07350-6.

Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma.

Huynh J, Cho M, Monjazeb A, Al-Obeidi E, Singh A, Tam K Invest New Drugs. 2023; 42(1):35-43.

PMID: 38038862 PMC: 10891185. DOI: 10.1007/s10637-023-01416-w.

PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients.

Asghar K, Bashir S, Rana I, Bakar M, Farooq A, Hassan M J Hepatocell Carcinoma. 2023; 10:921-934.

PMID: 37350801 PMC: 10284167. DOI: 10.2147/JHC.S409741.

References

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y . Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res. 2005; 11(16):6030-9. DOI: 10.1158/1078-0432.CCR-04-2671. View

Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A . CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002; 3(11):1097-101. DOI: 10.1038/ni846. View

von Bergwelt-Baildon M, Popov A, Saric T, Chemnitz J, Classen S, Stoffel M . CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood. 2006; 108(1):228-37. DOI: 10.1182/blood-2005-08-3507. View

Zou W . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5(4):263-74. DOI: 10.1038/nrc1586. View

Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C . Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006; 12(4):1144-51. DOI: 10.1158/1078-0432.CCR-05-1966. View

Fallarino F, Grohmann U, You S, McGrath B, Cavener D, Vacca C . The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006; 176(11):6752-61. DOI: 10.4049/jimmunol.176.11.6752. View

Astigiano S, Morandi B, Costa R, Mastracci L, DAgostino A, Ratto G . Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia. 2005; 7(4):390-6. PMC: 1501151. DOI: 10.1593/neo.04658. View

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

Munn D, Sharma M, Mellor A . Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol. 2004; 172(7):4100-10. DOI: 10.4049/jimmunol.172.7.4100. View

10.

Munn D, Shafizadeh E, Attwood J, Bondarev I, Pashine A, Mellor A . Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999; 189(9):1363-72. PMC: 2193062. DOI: 10.1084/jem.189.9.1363. View

11.

Mellor A, Munn D . IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004; 4(10):762-74. DOI: 10.1038/nri1457. View

12.

Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O . Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 2007; 98(6):874-81. PMC: 11159745. DOI: 10.1111/j.1349-7006.2007.00470.x. View

13.

Mellor A, Munn D . Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?. Immunol Today. 1999; 20(10):469-73. DOI: 10.1016/s0167-5699(99)01520-0. View

14.

Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E . Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood. 2006; 109(7):2871-7. DOI: 10.1182/blood-2006-07-036863. View

15.

Munn D, Mellor A . Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007; 117(5):1147-54. PMC: 1857253. DOI: 10.1172/JCI31178. View

16.

Lee J, Torisu-Itakara H, Cochran A, Kadison A, Huynh Y, Morton D . Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res. 2005; 11(1):107-12. View

17.

Munn D, Sharma M, Lee J, Jhaver K, Johnson T, Keskin D . Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002; 297(5588):1867-70. DOI: 10.1126/science.1073514. View

18.

Munn D, Sharma M, Hou D, Baban B, Lee J, Antonia S . Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004; 114(2):280-90. PMC: 449750. DOI: 10.1172/JCI21583. View

19.

Takikawa O, Yoshida R, Kido R, HAYAISHI O . Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J Biol Chem. 1986; 261(8):3648-53. View

20.

Tang Z . Hepatocellular carcinoma. J Gastroenterol Hepatol. 2000; 15 Suppl:G1-7. DOI: 10.1046/j.1440-1746.2000.02257.x. View